Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 546

1.

Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.

Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, Iwakami S, Moriyama M, Moriyama H, Koizumi F, Takahashi K.

PLoS One. 2014 Jan 28;9(1):e86459. doi: 10.1371/journal.pone.0086459. eCollection 2014.

2.

Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.

Kobayashi I, Takahashi F, Nurwidya F, Nara T, Hashimoto M, Murakami A, Yagishita S, Tajima K, Hidayat M, Shimada N, Suina K, Yoshioka Y, Sasaki S, Moriyama M, Moriyama H, Takahashi K.

Biochem Biophys Res Commun. 2016 Apr 22;473(1):125-132. doi: 10.1016/j.bbrc.2016.03.064. Epub 2016 Mar 17.

PMID:
26996130
3.

Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.

Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H, Seyama K, Nishio K, Takahashi K.

Cancer Sci. 2012 Nov;103(11):1946-54. doi: 10.1111/j.1349-7006.2012.02408.x. Epub 2012 Sep 14.

4.

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, Hirsch FR.

Cell Oncol (Dordr). 2013 Jul;36(4):277-88. doi: 10.1007/s13402-013-0133-9. Epub 2013 Apr 26.

5.

Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.

Choi JM, Jang JY, Choi YR, Kim HR, Cho BC, Lee HW.

Lung Cancer. 2015 Nov;90(2):175-81. doi: 10.1016/j.lungcan.2015.08.019. Epub 2015 Sep 3.

PMID:
26342551
6.

Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.

Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW.

Mol Cancer Ther. 2016 Jun;15(6):1387-96. doi: 10.1158/1535-7163.MCT-15-0089. Epub 2016 Feb 16.

7.

Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.

Nurwidya F, Takahashi F, Kobayashi I, Murakami A, Kato M, Minakata K, Nara T, Hashimoto M, Yagishita S, Baskoro H, Hidayat M, Shimada N, Takahashi K.

Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):332-8. doi: 10.1016/j.bbrc.2014.11.014. Epub 2014 Nov 15.

PMID:
25446090
8.

Enrichment and characterization of cancer stem cells from a human non-small cell lung cancer cell line.

Zhao C, Setrerrahmane S, Xu H.

Oncol Rep. 2015 Oct;34(4):2126-32. doi: 10.3892/or.2015.4163. Epub 2015 Jul 30.

PMID:
26239272
9.

Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Segura-Carretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA.

Cell Cycle. 2013 Nov 1;12(21):3390-404. doi: 10.4161/cc.26417. Epub 2013 Sep 17.

10.

Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.

Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH.

Cancer. 2011 Jul 1;117(13):2970-85. doi: 10.1002/cncr.25869. Epub 2011 Jan 10.

11.

Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.

Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C.

J Cell Physiol. 2012 Jul;227(7):2947-52. doi: 10.1002/jcp.23041.

PMID:
21959795
12.

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.

Lee Y, Wang Y, James M, Jeong JH, You M.

Mol Carcinog. 2016 May;55(5):991-1001. doi: 10.1002/mc.22342. Epub 2015 Jun 4.

PMID:
26052929
13.

miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.

Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X, Peng L, Sun J, Chen Z.

Int J Oncol. 2016 May;48(5):1855-67. doi: 10.3892/ijo.2016.3401. Epub 2016 Feb 19.

14.

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.

Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.

Oncotarget. 2015 Dec 29;6(42):44274-88. doi: 10.18632/oncotarget.6236.

15.

β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.

Fang X, Gu P, Zhou C, Liang A, Ren S, Liu F, Zeng Y, Wu Y, Zhao Y, Huang B, Zhang Z, Yi X.

Pulm Pharmacol Ther. 2014 Jun;28(1):41-8. doi: 10.1016/j.pupt.2013.05.005. Epub 2013 May 23.

PMID:
23707949
16.

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.

La Monica S, Madeddu D, Tiseo M, Vivo V, Galetti M, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Falco A, Gervasi A, Lagrasta CA, Naldi N, Barocelli E, Ardizzoni A, Quaini F, Petronini PG, Alfieri R.

J Thorac Oncol. 2016 Jul;11(7):1051-63. doi: 10.1016/j.jtho.2016.03.006. Epub 2016 Mar 19.

17.

TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.

Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Mol Cancer Ther. 2010 Oct;9(10):2785-92. doi: 10.1158/1535-7163.MCT-10-0481. Epub 2010 Aug 17.

18.

Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.

Tominaga T, Tsuchiya T, Mochinaga K, Arai J, Yamasaki N, Matsumoto K, Miyazaki T, Nagasaki T, Nanashima A, Tsukamoto K, Nagayasu T.

BMC Cancer. 2016 Jun 6;16:354. doi: 10.1186/s12885-016-2392-0.

19.

Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.

Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM.

Oncogene. 2009 Nov 12;28(45):3949-59. doi: 10.1038/onc.2009.252. Epub 2009 Aug 31.

PMID:
19718046
20.

Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.

Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.

Int J Oncol. 2013 Jun;42(6):2094-102. doi: 10.3892/ijo.2013.1895. Epub 2013 Apr 12.

PMID:
23588221

Supplemental Content

Support Center